Analytical Data
-
Gene name
Coagulation Factor VII/F7
- Application
-
Alternative Names
Proconvertin Serum prothrombin conversion accelerator Short name: SPCA INN: Eptacog alfa Cleaved into the following 2 chains: Factor VII light chain Factor VII heavy chain
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08709
-
Expression Region
61-212aa
-
Molecular Weight
33 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor VII (FVII) is a crucial protein in the blood coagulation cascade, playing a pivotal role in hemostasis by initiating the extrinsic pathway of coagulation. Deficiency or dysfunction of FVII is linked to bleeding disorders, necessitating novel therapeutic approaches. Recombinant FVII (rFVIIa) has emerged as a vital therapeutic agent, particularly for patients with FVII deficiency, hemophilia, and those experiencing uncontrolled bleeding, such as in surgical settings or trauma. The production of rFVIIa through recombinant DNA technology has enabled a consistent and purified source, addressing issues related to transmission of infectious diseases associated with plasma-derived products. Current research focuses on optimizing the production processes to enhance yield and activity, exploring its potential in the treatment of bleeding complications beyond inherited disorders, and understanding its mechanisms at the molecular level to improve efficacy and safety. Investigations into the pharmacokinetics, dose-response relationships, and potential adverse effects are ongoing to refine treatment protocols. Additionally, the development of new formulations aims to extend the therapeutic window of rFVII, making it a more versatile option for diverse clinical applications. The continued exploration of FVII and its recombinant forms is crucial for advancing treatments for coagulation disorders, ultimately aimed at improving patient outcomes and quality of life.
